A systematic review and meta-analysis on the safety and efficacy of febuxostat versus allopurinol in chronic gout

Seminars in Arthritis and Rheumatism

Volumn 43, Issue 3, 2013, Pages 367-375

  Faruque, Labib I ^a   Ehteshami Afshar, Arash ^a   Wiebe, Natasha ^a   Tjosvold, Lisa ^a   Homik, Joanne ^a   Tonelli, Marcello ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Allopurinol; Febuxostat; Gout; Meta analysis; Systematic review

Indexed keywords

ALLOPURINOL; FEBUXOSTAT; URIC ACID;

ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE EXACERBATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; GOUT; HUMAN; HYPERURICEMIA; LIVER DYSFUNCTION; LOW DRUG DOSE; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; URIC ACID BLOOD LEVEL;

ALLOPURINOL; FEBUXOSTAT; GOUT; META-ANALYSIS; SYSTEMATIC REVIEW;

ALLOPURINOL; GOUT; GOUT SUPPRESSANTS; HUMANS; HYPERURICEMIA; THIAZOLES; TREATMENT OUTCOME; URIC ACID;

EID: 84889565313     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2013.05.004     Document Type: Article

References (45)

1. Schumacher H.R. Crystal-induced arthritis: an overview. Am J Med 1996, 100(2A):46S-52S. [Epub 1996/02/26].
2. Doherty M. New insights into the epidemiology of gout. Rheumatology (Oxford) 2009, 48(Suppl. 2):ii2-ii8. [Epub 2009/11/13].
3. So A. Developments in the scientific and clinical understanding of gout. Arthritis Res Ther 2008, 10(5):221. [Epub 2008/10/25].
4. Teng G.G., Nair R., Saag KG Pathophysiology, clinical presentation and treatment of gout. Drugs 2006, 66(12):1547-1563. [Epub 2006/09/08].
5. Bomalaski J.S., Clark M.A. Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase. Curr Rheumatol Rep 2004, 6(3):240-247. [Epub 2004/05/12].
6. Cohen MG, Emmerson BT. Chapter 12: Gout. In: Klippel JH, Dieppe PA, editors. Rheumatology. London: Mosby; 1994. p. 1-16.
7. Schlesinger N. Management of acute and chronic gouty arthritis: present state-of-the-art. Drugs 2004, 64(21):2399-2416. [Epub 2004/10/16].
8. Schlesinger N. New agents for the treatment of gout and hyperuricemia: febuxostat, puricase, and beyond. Curr Rheumatol Rep 2010, 12(2):130-134. [Epub 2010/04/29].
9. Falasca G.F. Metabolic diseases: gout. Clin Dermatol 2006, 24(6):498-508. [Epub 2006/11/23].
10. Doghramji P.P. Managing your patient with gout: a review of treatment options. Postgrad Med J 2011, 123(3):56-71. [Epub 2011/05/14].
11. Terkeltaub R., Bushinsky D.A., Becker M.A. Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics. Arthritis Res Ther 2006, 8(Suppl. 1):S4. [Epub 2006/07/06].
12. El-Zawawy H., Mandell B.F. Managing gout: how is it different in patients with chronic kidney disease?. Cleve Clin J Med 2010, 77(12):919-928. [Epub 2010/12/15].
13. Burns C.M., Wortmann R.L. Gout therapeutics: new drugs for an old disease. Lancet 2011, 377(9760):165-177. [Epub 2010/08/20].
14. Terkeltaub R. Update on gout: new therapeutic strategies and options. Nat Rev Rheumatol 2010, 6(1):30-38. [Epub 2010/01/05].
15. Chohan S., Becker M.A. Update on emerging urate-lowering therapies. Curr Opin Rheumatol 2009, 21:143-149. [Epub 2009/04/03].
16. Edwards N.L. Febuxostat: a new treatment for hyperuricaemia in gout. Rheumatology (Oxford) 2009, 48(Suppl. 2):ii15-ii19. [Epub 2009/11/13].
17. Wallace S.L., Robinson H., Masi A.T., Decker J.L., McCarty D.J., Yu T.F. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977, 20(3):895-900. [Epub 1977/04/01].
18. Schumacher H.R., Taylor W., Joseph-Ridge N., Perez-Ruiz F., Chen L.X., Schlesinger N., et al. Outcome evaluations in gout. J Rheumatol 2007, 34(6):1381-1385. [Epub 2007/06/07].
19. Schumacher H.R., Taylor W., Edwards L., Grainger R., Schlesinger N., Dalbeth N., et al. Outcome domains for studies of acute and chronic gout. J Rheumatol 2009, 36(10):2342-2345. [Epub 2009/10/13].
20. Taylor W.J., Schumacher H.R., Singh J.A., Grainger R., Dalbeth N. Assessment of outcome in clinical trials of gout-a review of current measures. Rheumatology (Oxford) 2007, 46(12):1751-1756. [Epub 2007/07/26].
21. Becker M.A., Schumacher H.R., Wortmann R.L., MacDonald P.A., Eustace D., Palo W.A., et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005, 353(23):2450-2461. [Epub 2005/12/13].
22. Facchini F.S. Near-iron deficiency-induced remission of gouty arthritis. Rheumatology (Oxford) 2003, 42(12):1550-1555. [Epub 2003/07/02].
23. Sarawate C.A., Patel P.A., Schumacher H.R., Yang W., Brewer K.K., Bakst A.W. Serum urate levels and gout flares: analysis from managed care data. J Clin Rheumatol 2006, 12(2):61-65. [Epub 2006/04/08].
24. Perez-Ruiz F., Liote F. Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout?. Arthritis Rheum 2007, 57(7):1324-1328. [Epub 2007/10/02].
25. Singh J.A., Taylor W.J., Simon L.S., Khanna P.P., Stamp L.K., McQueen F.M., et al. Patient-reported outcomes in chronic gout: a report from OMERACT 10. J Rheumatol 2011, 38(7):1452-1457. [Epub 2011/07/05].
26. Dalbeth N., Schauer C., Macdonald P., Perez-Ruiz F., Schumacher H.R., Hamburger S., et al. Methods of tophus assessment in clinical trials of chronic gout: a systematic literature review and pictorial reference guide. Ann Rheum Dis 2011, 70(4):597-604. [Epub 2011/01/11].
27. Dalbeth N., McQueen F.M., Singh J.A., MacDonald P.A., Edwards N.L., Schumacher H.R., et al. Tophus measurement as an outcome measure for clinical trials of chronic gout: progress and research priorities. J Rheumatol 2011, 38(7):1458-1461. [Epub 2011/07/05].
28. Bionichepharma. Aloprim (allopurinol sodium) for injection. Product information 005863, http://www.bionichepharmausa.com/pdf/aloprim.pdf.
29. Lefebvre C., Manheimer E., Glanville J. Chapter 6: Searching for studies. Cochrane handbook for systematic reviews of interventions: the Cochrane Collaboration 2011, Available from www.cochrane-handbook.org. J.P.T. Higgins, S. Green (Eds.).
30. Higgins J.P.T., Altman D.G., Sterne J.A.C. Chapter 8: Assessing risk of bias in included studies. Cochrane handbook for systematic reviews of interventions: the Cochrane Collaboration 2011, Available from www.cochrane-handbook.org. J.P.T. Higgins, S. Green (Eds.).
31. Wiebe N., Vandermeer B., Platt R.W., Klassen T.P., Moher D., Barrowman N.J. A systematic review identifies a lack of standardization in methods for handling missing variance data. J Clin Epidemiol 2006, 59(4):342-353. [Epub 2006/03/22].
32. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. Br Med J 2003, 327(7414):557-560. [Epub 2003/09/06].
33. Becker M.A., Schumacher H.R., Espinoza L.R., Wells A.F., MacDonald P., Lloyd E., et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther 2010, 12(2):R63. [Epub 2010/04/08].
34. Kamatani N., Fujimori S., Hada T., Hosoya T., Kohri K., Nakamura T., et al. An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study. J Clin Rheumatol 2011, 17(4 Suppl. 2):S13-18. [Epub 2011/07/29].
35. Naoyuki K., Shin F., Toshikazu H., Tatsuo H., Kenjiro K., Toshitaka N., et al. An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 2 exploratory clinical study. J Clin Rheumatol 2011, 17(4 Suppl. 2):S44-49. [Epub 2011/07/29].
36. Schumacher H.R., Becker M.A., Wortmann R.L., Macdonald P.A., Hunt B., Streit J., et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 2008, 59(11):1540-1548. [Epub 2008/11/01].
37. Singal K.K., Goyal S., Gupta P., Aggawal B.K. Comparison between allopurinol and febuxostat in management of gout patients-a prospective study. Bangladesh J Med Sci 2011, 10(4):257-259.
38. Becker M.A., Schumacher H.R., MacDonald P.A., Lloyd E., Lademacher C. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol 2009, 36(6):1273-1282. [Epub 2009/03/17].
39. FDA. Name of drug: Uloric. Indication: management of hyperuricemia in patients with gout. Centre for Drug evaluation and Research. Food and Drug Administration; 2009 [Contract no.: NDA 21-856/N0046].
40. EMA. CHMP assessment report for adenuric. European Medicines Agency; 2008 [Contract no.: EMEA/258531/2008].
41. Wortmann R.L., Macdonald P.A., Hunt B., Jackson R.L. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. Clin Ther 2010, 32(14):2386-2397. [Epub 2011/03/01].
42. Khanna P., Singh M.K., Bae S., FitzGerald J.D., Prakash S., Kaldas M., et al. Oral urate lowering therapies in chronic gout: a systematic review and meta-analysis. Arthritis Rheum 2011, 63(10). [S405-S].
43. Lopez-Olivo M.A., Tayar J.H., Suarez-Almazor M.E. Febuxostat for the treatment of chronic recurrent gout: a meta-analysis. Ann Rheum Dis 2010, 69(3):608.
44. Lo T.E.N., Aherrera J.A.M., Taguba A.Q., Penserga E.G. Febuxostat versus allopurinol for hyperuricemia and gout: a meta-analysis (Fame study). Ann Rheum Dis 2011, 70(3):687.
45. Khanna D., Fitzgerald J.D., Khanna P.P., Bae S., Singh M.K., Neogi T., et al. American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res 2012, 64(10):1431-1446. [Epub 2012/10/02].